Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress

Jean-Marie Forel1, Antoine Roch, Valérie Marin

  • 1Réanimation Médicale, Assistance Publique Hôpitaux de Marseille, Hôpital Sainte Marguerite, Marseille, France.

Critical Care Medicine
|August 26, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognosis of critically ill patients with severe acute kidney injury and high circulating dipeptidyl peptidase 3: a post hoc analysis of the AKIKI 2 trial.

Critical care (London, England)·2026
Same author

A prospective clinical evaluation of new ECCO2R technology in mild to moderate ARDS patients: assessing ultra-lung-protective ventilation with PRISMALUNG.

Critical care (London, England)·2026
Same author

Multiplex PCR in Donor and Recipient Bronchoalveolar Lavage to Guide Early Antibiotic Prophylaxis Adaptation in Lung Transplantation: A Single-Center Cohort Study.

Journal of clinical medicine·2025
Same author

Short-term exposure to air pollution does not alter the outcome of ARDS in Europe.

Journal of epidemiology and population health·2025
Same author

Early versus late 2 mg/kg methylprednisolone therapy in ARDS.

Scientific reports·2025
Same author

Correction: Heterogenous treatment effect of neuromuscular blocking agents for moderate-to-severe ARDS: a post hoc Markov model re-analysis of the ACURASYS trial.

Intensive care medicine·2025
Same journal

The authors reply.

Critical care medicine·2026
Same journal

Attracting Emergency Medicine Graduates to Surgical Critical Care Training Programs.

Critical care medicine·2026
Same journal

The authors reply.

Critical care medicine·2026
Same journal

Beyond a Snapshot: Tracking Family Prognostic Expectations in the ICU.

Critical care medicine·2026
Same journal

The authors reply.

Critical care medicine·2026
Same journal

Plasma Levels of Soluble ST2 Reflect Extrapulmonary Organ Dysfunction and Predict Outcomes in Acute Respiratory Failure: Beware of Potential Confounders.

Critical care medicine·2026
See all related articles

Early use of neuromuscular blocking agents (NMBAs) in acute respiratory distress syndrome (ARDS) reduces inflammation. This intervention improved oxygenation and decreased key inflammatory markers in patients on mechanical ventilation.

Area of Science:

  • Critical Care Medicine
  • Pulmonology
  • Pharmacology

Background:

  • Acute Respiratory Distress Syndrome (ARDS) is characterized by significant pulmonary and systemic inflammation.
  • Mechanical ventilation, while life-saving, can exacerbate inflammation in ARDS patients.
  • Neuromuscular blocking agents (NMBAs) have been explored for their potential anti-inflammatory effects in critical illness.

Purpose of the Study:

  • To investigate the impact of early NMBAs administration on inflammatory markers in ARDS patients.
  • To assess the effect of NMBAs on pulmonary and systemic inflammation during lung-protective mechanical ventilation.
  • To evaluate the influence of NMBAs on gas exchange, specifically the Pao2/Fio2 ratio, in ARDS.

Main Methods:

  • A multi-center, prospective, randomized controlled trial involving 36 ARDS patients.

Related Experiment Videos

  • Patients received either conventional therapy plus placebo or conventional therapy plus NMBAs for 48 hours.
  • Both groups were managed with a lung-protective ventilation strategy; bronchoalveolar lavage and blood samples were collected to measure inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8).

    • Main Results:

    • NMBAs group showed a significant decrease in pulmonary IL-8 concentrations over time.
    • At 48 hours, pulmonary IL-1β, IL-6, and IL-8 were significantly lower in the NMBA group compared to controls.
    • Serum IL-1β and IL-6 were also reduced in the NMBA group, alongside a sustained improvement in the Pao2/Fio2 ratio.

    Conclusions:

    • Early administration of NMBAs effectively reduces the pro-inflammatory response in ARDS patients.
    • NMBAs contribute to decreased pulmonary and systemic inflammation associated with mechanical ventilation in ARDS.
    • The use of NMBAs in ARDS patients on lung-protective ventilation is associated with improved oxygenation.